A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yearly, and oral risedronate, 5 mg daily, in the prevention and treatment of corticosteroid induced osteoporosis

Trial Profile

A multinational, multicenter, randomized, double-blind, double-dummy, stratified, active controlled parallel group study comparing the efficacy and safety of intravenous zoledronic acid, 5 mg once yearly, and oral risedronate, 5 mg daily, in the prevention and treatment of corticosteroid induced osteoporosis

Completed
Phase of Trial: Phase III

Latest Information Update: 24 May 2017

At a glance

  • Drugs Zoledronic acid (Primary) ; Corticosteroids; Risedronic acid
  • Indications Osteoporosis
  • Focus Pharmacodynamics
  • Sponsors Novartis; Novartis Pharmaceuticals
  • Most Recent Events

    • 07 Feb 2015 Planned number of patients changed from 802 to 900 as per European Clinical Trial Register record.
    • 03 May 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top